These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 8841156

  • 1. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
    Fernández de Gatta MD, Calvo MV, Hernández JM, Caballero D, San Miguel JF, Domínguez-Gil A.
    Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
    [Abstract] [Full Text] [Related]

  • 2. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L, Encinas MP, Morín LS, Vilches P, Gutiérrez N, García-Sanz R, Caballero D, Hurlé AD.
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [Abstract] [Full Text] [Related]

  • 3. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J.
    Acta Pol Pharm; 2005 Mar; 62(6):491-5. PubMed ID: 16583990
    [Abstract] [Full Text] [Related]

  • 4. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J.
    Acta Pol Pharm; 2005 Mar; 62(6):485-90. PubMed ID: 16583989
    [Abstract] [Full Text] [Related]

  • 5. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A, Palau E, Puerro M, Vargas E, Picazo JJ.
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [Abstract] [Full Text] [Related]

  • 6. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
    Masuda N, Maiguma T, Komoto A, Haruki Y, Sugiyama T, Kondo S, Teshima D.
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
    [Abstract] [Full Text] [Related]

  • 7. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
    Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM.
    Pharmacotherapy; 1990 Apr; 10(6):378-82. PubMed ID: 2287556
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
    Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA.
    J Antimicrob Chemother; 2008 Jul; 62(1):168-71. PubMed ID: 18334494
    [Abstract] [Full Text] [Related]

  • 9. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
    Han HK, An H, Shin KH, Shin D, Lee SH, Kim JH, Cho SH, Kang HR, Jang IJ, Yu KS, Lim KS.
    Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
    [Abstract] [Full Text] [Related]

  • 10. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
    Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL.
    Clin Infect Dis; 2009 Aug 15; 49(4):507-14. PubMed ID: 19586413
    [Abstract] [Full Text] [Related]

  • 11. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS, Sorensen SV, Liu LZ, Itani KM.
    Ann Pharmacother; 2006 Jun 15; 40(6):1017-23. PubMed ID: 16720705
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.
    Zhang Y, Wang T, Zhang D, You H, Dong Y, Liu Y, Du Q, Sun D, Zhang T, Dong Y.
    Ther Drug Monit; 2020 Aug 15; 42(4):600-609. PubMed ID: 32097248
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity.
    Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE.
    Pharmacotherapy; 2003 May 15; 23(5):643-50. PubMed ID: 12741439
    [Abstract] [Full Text] [Related]

  • 15. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
    Bhavnani SM, Prakhya A, Hammel JP, Ambrose PG.
    Clin Infect Dis; 2009 Sep 01; 49(5):691-8. PubMed ID: 19635023
    [Abstract] [Full Text] [Related]

  • 16. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.
    Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E.
    Anesthesiology; 2009 Aug 01; 111(2):356-65. PubMed ID: 19602966
    [Abstract] [Full Text] [Related]

  • 17. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
    Codina C, Miró JM, Tuset M, Claramonte J, Gomar C, Gotsens R, Gómez B, Suárez S, Abellana R, Ascaso C, Cartaña R, Rodríguez E, Asenjo M, Carné X, Trilla A, Marco F, Gómez J, Brunet M, Pomar JL, Gatell JM, Ribas J.
    Med Clin (Barc); 2000 Aug 01; 114 Suppl 3():54-61. PubMed ID: 10994565
    [Abstract] [Full Text] [Related]

  • 18. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
    Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH.
    Clin Ther; 2007 Jun 01; 29(6):1107-15. PubMed ID: 17692725
    [Abstract] [Full Text] [Related]

  • 19. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.
    Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB.
    Am J Med; 2010 Dec 01; 123(12):1143-9. PubMed ID: 21183005
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.